Level B· Emerging clinical evidence with positive signalsClinical TrialEurope PMCOpen access

Towards an in vitro fibrogenesis model of human vocal fold scarring

Graupp M., Rinner B., Frisch MT., Weiss G., Fuchs J., Sundl M.

Clinical Trial on Scar, published in Eur Arch Otorhinolaryngol (2018) — summary generated from the PubMed abstract.

Open my reading list
Level B· Emerging clinical evidence with positive signalsEvidence level of this study

Several human studies show positive signals, while research methods and sample sizes continue to develop.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Clinical Trial
Journal
Eur Arch Otorhinolaryngol (2018)
Reported sample size
—
Source database
Europe PMC
PMID
29520499
PMCID
PMC5893733
DOI
10.1007/s00405-018-4922-7
Citations
21

Abstract (original English)

Background Vocal fold (VF) scarring remains a therapeutic dilemma and challenge in modern laryngology. To facilitate corresponding research, we aimed to establish an in vitro fibrogenesis model employing human VF fibroblasts (hVFF) and the principles of macromolecular crowding (MMC). Methods Fibrogenesis was promoted by addition of transforming growth factor-β1 to standard medium and medium containing inert macromolecules (MMC). Hepatocyte growth factor (HGF) and Botox type A were tested for their antifibrotic properties in various doses. Experiments were analyzed with respect to the biosynthesis of collagen, fibronectin, and α-smooth muscle actin using immunofluorescence, silver stain and western blot. Results MMC led to favourable enhanced deposition of collagen and other extracellular matrix components, reflecting fibrotic conditions. Low doses of HGF were able to dampen profibrotic effects. This could not be observed for higher HGF concentrations. Botox type A did not show any effects. Conclusion Based on the principles of MMC we could successfully establish a laryngeal fibrogenesis model employing hVFF. Our finding of dose-dependent HGF effects is important before going into clinical trials in humans and has never been shown before. Our model provides a novel option to screen various potential antifibrotic compounds under standardized conditions in a short time.

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.

Evidence level

Several human studies show positive signals, while research methods and sample sizes continue to develop.

How we grade evidence
Vocal CordsCicatrixCells, CulturedFibroblastsHumansFibrosisHepatocyte Growth FactorFluorescent Antibody TechniqueBlotting, WesternIn Vitro Techniques

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research